Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886543 | 0.91 | L3MBTL1 (0.46) | L3MBTL1CAPN1FTOMAPTPOLB | |
| SCHEMBL22886761 | 0.89 | RAB9A (0.40) | L3MBTL1CAPN1FTOMAPTPOLB | |
| SCHEMBL20027860 | 0.89 | CAPN1 (0.52) | L3MBTL1CAPN1 | |
| SCHEMBL21410716 | 0.88 | FTO (0.42) | L3MBTL1CAPN1FTOMAPTPOLB | |
| SCHEMBL22886561 | 0.86 | L3MBTL1 (0.42) | L3MBTL1CAPN1FTOMAPTPOLB | |
| SCHEMBL22886453 | 0.83 | EPHX2 (0.45) | CAPN1 | |
| SCHEMBL22886566 | 0.83 | CAPN1 (0.43) | CAPN1 | |
| SCHEMBL22886592 | 0.82 | MAPT (0.35) | L3MBTL1CAPN1FTOMAPTPOLB | |
| SCHEMBL20028433 | 0.81 | CAPN1 (0.48) | L3MBTL1CAPN1 | |
| SCHEMBL22886851 | 0.81 | CAPN1 (0.38) | CAPN1FTOMAPTPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | L3MBTL1 3275/4885CAPN1 3/4885FTO 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.